Drugs / Solvazinc
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 0 | NCT05605886 Comparator | May 2022 → Apr 2023 | myofascial pain syndrome, salivary substance, Clostridium botulinum type | Cairo University | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Solvazinc | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05605886 ↗ |